WHO-GMP certification requirements for African market entry
Introduction
Ask any pharmaceutical exporter what the single most repeated requirement is across NAFDAC, PPB Kenya, and FDA Ghana applications, and the answer is the same: WHO-GMP certification. It’s the one credential that shows up in every registration dossier, every buyer due-diligence checklist, and increasingly, every tender document across African markets.
Understanding WHO-GMP certification requirements for African market entry isn’t just a compliance checkbox — it’s often the difference between a manufacturer that gets shortlisted by distributors and one that doesn’t get a second look.
What WHO-GMP Certification Actually Confirms
WHO Good Manufacturing Practice regulations contain requirements for the methods, facilities, and controls used in the manufacture, processing, packaging, or holding of a pharmaceutical product, meant to ensure products meet the safety, quality, and efficacy they claim to represent. It’s a facility-level and systems-level certification — covering how a product is made, not just what the finished product tests as.
Because Africa lacks a single continental regulator, each country manages its own approval process through its own National Medicines Regulatory Authority, with distinct requirements, formats, and timelines — though the African Medicines Agency and regional harmonization initiatives are beginning to unify these approaches. Despite this fragmentation, every major African market accepts the CTD dossier format for registration, and WHO-GMP compliance is a consistent underlying expectation across them.
How WHO-GMP Is Verified Across Key African Markets
Nigeria (NAFDAC)
NAFDAC’s own GMP guidelines are explicitly structured around WHO good manufacturing practice principles for pharmaceutical products, and facility compliance with these standards underpins product registration eligibility.
Ghana (FDA Ghana)
FDA Ghana’s guideline on GMP requirements draws directly on WHO Technical Report Series guidance on good manufacturing practices for pharmaceutical products, forming the legal and technical basis for its facility inspection process. typical plant GMP audit for first-time registration reviews the pharmaceutical quality system, GMP compliance, sanitation and hygiene, qualification and validation, complaints handling, product recall procedures, and documentation practices — with the process taking approximately three months for a first-time audit and two months for renewal.
Kenya and Broader Regional Standards
Regulators increasingly calibrate GMP expectations against WHO-GMP and PIC/S-aligned practices, with reliance mechanisms allowing authorities to leverage prior trusted regulatory decisions, inspection reports, or WHO Prequalification outcomes to streamline national decisions — though this reliance remains at the discretion of each national authority.
What a WHO-GMP Facility Audit Typically Covers
Auditors generally expect documentation covering seventeen core areas at the manufacturing site, including:
- Pharmaceutical Quality System
- Good Manufacturing Practices for Pharmaceutical Products
- Sanitation and Hygiene
- Qualification and Validation
- Complaints Handling
- Product Recall Procedures
- Contract Production, Analysis, and Other Outsourced Activities
- Self-Inspection, Quality Audits, and Supplier Approval
- Personnel, Training, and Personal Hygiene
- Premises and Equipment
- Materials Handling
- Documentation Practices
- Good Practices in Production
- Good Practices in Quality Control
Deficiencies identified during inspection are classified as critical, major, or other, and are communicated to the manufacturer along with a requirement for corrective and preventive action.
Why WHO-GMP Matters Beyond Just Passing Registration
✔ It’s a prerequisite embedded in every downstream approval
COPP issuance, FSC applications, and product registration dossiers across Nigerian, Kenyan, and Ghanaian regulators all reference GMP compliance as foundational.
✔ Buyers use it as a shortlisting filter Distributors
and institutional buyers routinely screen out manufacturers who can’t produce current WHO-GMP documentation before even reviewing pricing.
✔ It supports faster registration through reliance mechanisms
As African regulators increasingly reference WHO Prequalification and prior trusted regulatory decisions, a strong existing GMP compliance record can streamline registration timelines rather than starting from zero each time.
✔ It signals credibility beyond the specific product
A facility-wide certification, rather than a single-product approval, tells buyers something about consistency across an entire manufacturing operation — not just one SKU.
Common Gaps That Delay or Fail GMP-Linked Approvals
Expired or Missing Registration Certificates Frequent issues include expired or missing registration certificates, nonconforming labels, incomplete batch documentation, and inadequate temperature-control records.
Documentation Not Aligned with the Approved Dossier Regulators expect submitted documents to align precisely with the approved dossier, alongside maintained, validated shipping evidence.
Incomplete Quality System Documentation Gaps in the seventeen core documentation areas — particularly self-inspection records and supplier approval processes — are common findings during facility audits.
Tips for Exporters Building Toward African Market Entry
✔ Treat WHO-GMP certification as a standing operational requirement, not a one-time project completed before your first export
✔ Keep documentation across all seventeen core audit areas current and audit-ready at all times, not assembled reactively before an inspection
✔ Maintain validated temperature-control and shipping records continuously, since these are frequently flagged gaps during review
✔ Where possible, pursue WHO Prequalification alongside national GMP compliance, since it increasingly supports faster registration through regulatory reliance mechanisms
Conclusion
WHO-GMP certification isn’t a single hurdle to clear before entering African markets — it’s the foundation that NAFDAC, PPB, and FDA Ghana registration processes are all built on top of, and increasingly, what buyers themselves screen for before any commercial conversation even starts. Manufacturers who treat GMP compliance as an ongoing operational standard, rather than a certificate to renew reactively, move through registration faster and win more buyer trust across every African market they enter.
Salvavidas Pharma, a WHO-GMP certified pharmaceutical manufacturer based in Surat, India, maintains this standard across its API, generics, oncology, and anti-HIV product lines specifically to support smooth, compliant entry into markets like Nigeria, Kenya, and Ghana.